NCT05761301 - A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

April 3, 2025

Study Completion Date

April 3, 2025

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

ALN-KHK

ALN-KHK will be administered by subcutaneous (SC) injection.

DRUG

Placebo

Placebo will be administered by subcutaneous (SC) injection.

Trial Locations (15)

Clinical Trial Site, Monroe

Clinical Trial Site, Atlanta

Clinical Trial Site, Orlando

Clinical Trial Site, Lake Worth

Clinical Trial Site, Oklahoma City

Clinical Trial Site, Dallas

Clinical Trial Site, Houston

Clinical Trial Site, San Antonio

Clinical Trial Site, Phoenix

Clinical Trial Site, Vista

Clinical Trial Site, Berlin

Clinical Trial Site, Sarnia

Clinical Trial Site, Montreal

Clinical Trial Site, Victoriaville

Clinical Trial Site, Toronto